宫颈上皮内瘤变治疗后的宫颈癌及其他恶性肿瘤发病与死亡风险:系统综述与荟萃分析
结果显示CIN治疗后宫颈癌发病率为39/10万妇女年,宫颈癌相对风险为3.30(95%CI 2.57-4.24),且风险在治疗后至少持续20年,50岁以上女性更高;阴道癌、外阴癌和肛门癌风险亦升高。
要点
- CIN治疗后宫颈癌风险较一般人群升高3.30倍,且至少持续20年。
- 50岁以上女性CIN治疗后宫颈癌相对风险更高。
- 阴道癌、外阴癌和肛门癌风险亦显著升高。
核心结论
- CIN治疗后女性后续诊断为宫颈癌及其他HPV相关癌症的风险显著高于一般人群。
- 宫颈癌高风险在治疗后至少持续20年,且50岁以上女性风险更高。
研究设计与样本
- 采用随机效应模型估计汇总效应。
主要发现
- CIN治疗后宫颈癌发病率为39/10万妇女年(95%CI 22-69)。
- 宫颈癌相对风险为3.30(95%CI 2.57-4.24;P<0.001)。
- 阴道癌相对风险为10.84(95%CI 5.58-21.10;P<0.001)。
- 外阴癌相对风险为3.34(95%CI 2.39-4.67;P<0.001)。
- 肛门癌相对风险为5.11(95%CI 2.73-9.55;P<0.001)。
关键数值与推荐
- 宫颈/阴道癌死亡相对风险为5.04(95%CI 0.69-36.94;P=0.073),估计不确定性较大。
临床怎么用
- 对于既往接受CIN治疗的女性,可能需要延长随访至末次筛查轮次之后。
局限性
- 宫颈/阴道癌死亡的相对风险估计不确定性较大(95%CI 0.69-36.94)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although local treatments for cervical intraepithelial neoplasia (CIN) are highly effective, it has been reported that treated women remain at increased risk of cervical and other cancers. Our aim is to explore the risk of developing or dying from cervical cancer and other human papillomavirus (HPV)- and non-HPV-related malignancies after CIN treatment and infer its magnitude compared with the general population. MATERIALS AND METHODS: Design: Systematic review and meta-analysis. Eligibility criteria: Studies with registry-based follow-up reporting cancer incidence or mortality after CIN treatment. DATA SYNTHESIS: Summary effects were estimated using random-effects models. OUTCOMES: Incidence rate of cervical cancer among women treated for CIN (per 100 000 woman-years). Relative risk (RR) of cervical cancer, other HPV-related anogenital tract cancer (vagina, vulva, anus), any cancer, and mortality, for women treated for CIN versus the general population. RESULTS: Twenty-seven studies were eligible. The incidence rate for cervical cancer after CIN treatment was 39 per 100 000 woman-years (95% confidence interval 22-69). The RR of cervical cancer was elevated compared with the general population (3.30, 2.57-4.24; P < 0.001). The RR was higher for women more than 50 years old and remained elevated for at least 20 years after treatment. The RR of vaginal (10.84, 5.58-21.10; P < 0.001), vulvar (3.34, 2.39-4.67; P < 0.001), and anal cancer (5.11, 2.73-9.55; P < 0.001) was also higher. Mortality from cervical/vaginal cancer was elevated, but our estimate was more uncertain (RR 5.04, 0.69-36.94; P = 0.073). CONCLUSIONS: Women treated for CIN have a considerably higher risk to be later diagnosed with cervical and other HPV-related cancers compared with the general population. The higher risk of cervical cancer lasts for at least 20 years after treatment and is higher for women more than 50 years of age. Prolonged follow-up beyond the last screening round may be warranted for previously treated women.
引用
- Kalliala I, Athanasiou A, Veroniki AA, et al. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol. 2020. PMID: 31959338. doi:10.1016/j.annonc.2019.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。